Innovent : China Approves TYVYT Combination As Treatment For Esophageal Squamous Cell Carcinoma

(RTTNews) – Innovent Biologics Inc. and Eli Lilly and Co. (LLY) said that the Center for Drug Evaluation of China’s National Medical Products Administration or NMPA has approved the supplemental New Drug Application or sNDA for TYVYT (sintilimab injection) in combination with cis

This post was originally published on this site